Abstract: A computer-implemented method includes a first module of a computing system receiving application-specific data for determining utilization attributes of multiple application programs. A second module of the system receives data for determining patient archetypes. A third module of the system determines a clinical benefit of each application program based on analysis of the application-specific data. The system matches an application program with a particular patient archetype based on analysis of each patient archetype and the determined clinical benefit of the application program. The system selects a particular application program for use by a patient of a first patient group based on: i) a characteristic of the first patient group that is included in a first patient archetype; and ii) the clinical benefit of the particular application exceeding a threshold clinical benefit.

Abstract: A method for producing a dehydrogenated product and a coked catalyst, then introducing an oxygen-containing fluid, combusting at least a portion of the coke disposed on the catalyst in the presence of the oxygen-containing fluid to produce a decoked catalyst. An apparatus for introducing fluid into a reactor, comprising a first inlet conduit configured to convey a first gas, a second inlet conduit configured to convey a second gas, and an outlet conduit configured to convey the first gas and the second gas into a reactor, wherein there is an acute angle between a longitudinal axes of the first inlet conduit and a longitudinal axis of the second inlet conduit and an obtuse angle between a longitudinal axis of the outlet conduit and the longitudinal axis of the second inlet conduit and a pre-distributor disposed, in one embodiment on the inner surface, within the first inlet conduit is disclosed.

Abstract: Described herein are materials and methods for improved catalytic oligomerization of an ethylene monomer and/or propylene monomer. The present disclosure teaches oligomerizing the ethylene monomer or propylene monomer to produce oligomers. Also described is a heterogeneous catalyst comprising sulfate modified nickel on titanium modified alumina and a surface modification with yttrium (Y) suitable for use in the disclosed oligomerization.

Abstract: A computer-implemented method includes a first module of a computing system receiving application-specific data for determining utilization attributes of multiple application programs. A second module of the system receives data for determining patient archetypes. A third module of the system determines a clinical benefit of each application program based on analysis of the application-specific data. The system matches an application program with a particular patient archetype based on analysis of each patient archetype and the determined clinical benefit of the application program. The system selects a particular application program for use by a patient of a first patient group based on: i) a characteristic of the first patient group that is included in a first patient archetype; and ii) the clinical benefit of the particular application exceeding a threshold clinical benefit.

Abstract: A method for producing a dehydrogenated product and a coked catalyst, then introducing an oxygen-containing fluid, combusting at least a portion of the coke disposed on the catalyst in the presence of the oxygen-containing fluid to produce a decoked catalyst. An apparatus for introducing fluid into a reactor, comprising a first inlet conduit configured to convey a first gas, a second inlet conduit configured to convey a second gas, and an outlet conduit configured to convey the first gas and the second gas into a reactor, wherein there is an acute angle between a longitudinal axes of the first inlet conduit and a longitudinal axis of the second inlet conduit and an obtuse angle between a longitudinal axis of the outlet conduit and the longitudinal axis of the second inlet conduit and a pre-distributor disposed, in one embodiment on the inner surface, within the first inlet conduit is disclosed.

Abstract: Described herein are materials and methods for improved catalytic oligomerization of an ethylene monomer and/or propylene monomer. The present disclosure teaches oligomerizing the ethylene monomer or propylene monomer to produce oligomers. Also described is a heterogeneous catalyst comprising sulfate modified nickel on titanium modified alumina and a surface modification with yttrium (Y) suitable for use in the disclosed oligomerization.

Abstract: Methods for dehydrogenating one or more alkanes. A catalyst can be contacted with an alkane under a pressure of less than 101 kPa to produce a coked catalyst and a dehydrogenated product. The dehydrogenated product can be separated from the coked catalyst and the coked catalyst can be contacted with a purge fluid to remove at least a portion of any residual alkane, any residual alkene, or a combination thereof from the coked catalyst. The coked catalyst can be contacted with an oxygen-containing fluid and at least a portion of the coke disposed on the catalyst can be combusted in the presence of the oxygen-containing fluid to produce a decoked catalyst. The decoked catalyst can be contacted with a reducing gas to produce a regenerated catalyst and an off-gas. Additional alkane can be contacted with the regenerated catalyst to produce additional dehydrogenated product and additional coked catalyst.

Abstract: Antibodies that bind specifically to receptor for advanced glycation end products (RAGE) and RAGE-binding fragments thereof are disclosed. Also disclosed are pharmaceutical compositions comprising such anti-RAGE antibodies and RAGE-binding antibody fragments thereof, and their use for treatment of RAGE related diseases.

Abstract: Compositions and methods for systemic administration of DNA encoding bone morphogenic proteins for promotion of osteogenesis are disclosed. The compositions and methods of the invention may be utilized for fracture repair. The invention further discloses compositions and methods for systemic administration of bone morphogenetic proteins for promotion of osteogenesis. These compositions and methods may be used in bone fracture healing and repair. These composition of the invention may be further utilized in increasing bone mineral density.

Abstract: Fusion proteins comprising a Receptor for Advanced Glycation End Products Ligand Binding Element (RAGE-LBE) and an immunoglobulin element are disclosed. Also disclosed are fusion proteins comprising a RAGE-LBE and a dimerization domain. Also disclosed are nucleic acids encoding such fusion proteins and methods for using disclosed nucleic acids and proteins to, for example, treat RAGE-related disorders. Additional compositions and methods are also disclosed.

Abstract: Compositions and methods for systemic administration of DNA encoding bone morphogenic proteins for promotion of osteogenesis are disclosed. The compositions and methods of the invention may be utilized for fracture repair. The invention further discloses compositions and methods for systemic administration of bone morphogenetic proteins for promotion of osteogenesis. These compositions and methods may be used in bone fracture healing and repair. These composition of the invention may be further utilized in increasing bone mineral density.

Abstract: Compositions and methods for systemic administration of DNA encoding bone morphogenic proteins for promotion of osteogenesis are disclosed. The compositions and methods of the invention may be utilized for fracture repair. The invention further discloses compositions and methods for systemic administration of bone morphogenetic proteins for promotion of osteogenesis. These compositions and methods may be used in bone fracture healing and repair. These composition of the invention may be further utilized in increasing bone mineral density.